Arbnora Batalli-Kepuska, L. Spahiu, E. Behluli, G. Temaj
{"title":"Blinatumomab vs Chemotherapy for Pediatric and Adult Acute Lymphoblastic Leukemia","authors":"Arbnora Batalli-Kepuska, L. Spahiu, E. Behluli, G. Temaj","doi":"10.21926/obm.genet.2403253","DOIUrl":null,"url":null,"abstract":"Several therapeutic methods are used to cure acute lymphoblastic leukemia (ALL). Relapsed/refractory B-cell ALL (R/R B-ALL) remains the primary cause of death worldwide due to the limitation of cure. Blinatumomab is a bispecific T-cell engaging antibody used to treat R/R B-ALL. The use of blinatumomab for treating R/R B-ALL has shown to be very efficient, especially as a bridge tool to hematopoietic stem cell transplantation (HSCT). The response to blinatumomab treatment ranged from 69% after two cycles in phase II clinical trials. Blinatumomab has shown great anti-leukemia activity as a single agent in children with R/R B-ALL. Here, we will review the data from several research groups that show pharmacological and clinical data on blinatumomab for pediatric and adult B-ALL, both as an immunotherapeutic and in combination.","PeriodicalId":503721,"journal":{"name":"OBM Genetics","volume":"1 24","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OBM Genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21926/obm.genet.2403253","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Several therapeutic methods are used to cure acute lymphoblastic leukemia (ALL). Relapsed/refractory B-cell ALL (R/R B-ALL) remains the primary cause of death worldwide due to the limitation of cure. Blinatumomab is a bispecific T-cell engaging antibody used to treat R/R B-ALL. The use of blinatumomab for treating R/R B-ALL has shown to be very efficient, especially as a bridge tool to hematopoietic stem cell transplantation (HSCT). The response to blinatumomab treatment ranged from 69% after two cycles in phase II clinical trials. Blinatumomab has shown great anti-leukemia activity as a single agent in children with R/R B-ALL. Here, we will review the data from several research groups that show pharmacological and clinical data on blinatumomab for pediatric and adult B-ALL, both as an immunotherapeutic and in combination.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
